BioTex is committed to innovating and developing optical solutions to medical, biomedical, and environmental problems. Our current research focuses on early stage development of both diagnostic and therapeutic medical applications. Our goal in this mission is to build value in new technologies by directing effective research and development programs and demonstrating performance and commercial utility of promising new devices and procedures. BioTex is a registered FDA manufacturer and has developed products from concept to FDA 510(k) cleared medical devices.

VisualaseĀ® System
Visualase is a laser technology that utilizes light energy to destroy soft tissue including tumor or damaged tissue. Laser energy is delivered to the target area (the lesion) using a laser probe. As light is delivered through the laser probe temperatures in the target area begin to rise, destroying the unwanted tissue. Because Visualase procedures are guided by MRI images, the procedure can provide precise targeting. The procedure is minimally invasive and has been reported in medical journals to be pain free and require a short recovery time.
Read more at visualaseinc.com

Other developments and products
A primary area of research for BioTex is the use of lasers for medical therapy. Lasers offer tremendous potential for surgical applications. There are a host of applications in which the ability to deliver large and selective doses of energy to almost any location in the body via small flexible optical fiber would allow for a significant reduction in surgical trauma and a concomitant reduction in patient recovery time and associated healthcare costs. For a number of reasons, this potential has yet to be fully realized, and lasers remain primarily rooted in dermatological (skin) and ophthalmological (eye) applications. BioTex is capitalizing on its expertise in thermal modeling, laser-tissue interaction, and optical and biomedical engineering to develop techniques and devices which broaden the horizon of laser therapeutic procedures.

See more…

 

Comments are closed.